---
id: idsa-cabp-2024
title: "IDSA 2024 Clinical Practice Guideline for Antibiotic Therapy of Community-Acquired Bacterial Pneumonia in Adults"
short_title: "IDSA CABP 2024"

organization: Infectious Diseases Society of America
collaborators:
  - American Thoracic Society
country: US
url: https://www.idsociety.org/guidelines/
doi: null
pmid: null
open_access: true

specialty: infectious-disease
guideline_type: clinical-practice
evidence_system: IDSA GRADE
conditions:
  - community-acquired pneumonia
  - CAP
  - bacterial pneumonia
tags:
  - amoxicillin
  - respiratory fluoroquinolones
  - macrolides
  - doxycycline
  - severity assessment

publication_date: 2024-10-01
previous_version_date: 2019-10-01
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-24
---

## Scope
2024 update to the IDSA/ATS guideline for antibiotic treatment of community-acquired bacterial pneumonia (CABP) in adults.

## Key Recommendations

### Diagnosis
- Obtain a chest radiograph or CT when CAP is suspected.
- Procalcitonin: May help guide decisions to initiate or discontinue antibiotics but should not override clinical judgment.

### Risk Stratification
- Use validated scores (PSI/PORT, CURB-65) to guide site of care decisions (outpatient, ward, ICU).

### Empiric Antibiotic Therapy

#### Outpatient (Healthy, No Comorbidities, No Recent Antibiotics, No Risk Factors for Resistant Pathogens)
- **First-Line**: Amoxicillin (1 g TID).
- **Alternatives**: Doxycycline OR a macrolide (azithromycin or clarithromycin) if local resistance <25%.

#### Outpatient (Comorbidities: COPD, diabetes, heart/liver/renal disease, malignancy, immunocompromise, or recent antibiotic use)
- Amoxicillin-clavulanate OR a cephalosporin (e.g., cefpodoxime, cefuroxime) PLUS a macrolide or doxycycline.
- OR a respiratory fluoroquinolone monotherapy (levofloxacin, moxifloxacin).

#### Inpatient (Non-ICU)
- **Preferred**: Beta-lactam (ceftriaxone, cefotaxime, ampicillin-sulbactam) PLUS a macrolide.
- **Alternative**: Respiratory fluoroquinolone monotherapy.

#### Inpatient (ICU, Severe CAP)
- Beta-lactam (ceftriaxone, cefotaxime, ampicillin-sulbactam) PLUS a macrolide (azithromycin) OR a respiratory fluoroquinolone.
- If Pseudomonas or MRSA risk factors are present, modify coverage accordingly.

### Duration
- Minimum 5 days; extend if clinically unstable or slowly responding.

### Special Considerations
- **MRSA Risk**: Add vancomycin or linezolid.
- **Pseudomonas Risk**: Use anti-pseudomonal beta-lactam.
